Abcam, ab129729, Anti-UGT antibody [7H2AF11]

Size: 100µg
Mouse Monoclonal UGT1A9 antibody. Suitable for IHC-P, IP, Flow Cyt, ICC/IF and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:7H2AF11,
Isotype:IgG1,
Light chain type:kappa,
Carrier free:No,
Reacts with:Human,
Applications:Flow Cyt, ICC/IF, IHC-P, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.

Product details:
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com

Properties and Storage Information:
Form-Liquid, Purification notes-Purity is near homogeneity as judged by SDS-PAGE. ab129729 was produced in vitro using hybridomas grown in serum-free medium, and then purified by biochemical fractionation., Storage buffer-pH: 7.5Preservative: 0.02% Sodium azideConstituents: 99% HEPES buffered saline, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein UGT also known as UDP-glucuronosyltransferase plays a significant role in the process of glucuronidation. Mechanically UGT facilitates the transfer of glucuronic acid from UDP-glucuronic acid to various substrates including hormones and drugs which increases their solubility in water. The mass of UGT proteins can vary depending on isoform types generally ranging from 50 to 60 kDa. UGT is mainly expressed in the liver but it is also found in the intestine kidneys and other tissues reflecting its comprehensive role in metabolism.
Biological function summary
The UGT enzymes function in detoxification processes by converting lipophilic substances into more water-soluble metabolites which can then be excreted from the body. UGT forms part of a multienzyme complex involved in phase II drug metabolism. It also interacts with other enzymes involved in conjugation pathways like sulfotransferases to ensure efficient and effective elimination of potentially harmful compounds.
Pathways
UGT enzymes play a pivotal role in the glucuronidation pathway which is a part of phase II of drug metabolism. This pathway connects to larger detoxification networks involving cytochrome P450 enzymes such as CYP3A4 which provide substrates for glucuronidation. Together these enzymes participate in xenobiotic metabolism impacting drug efficacy and safety by modifying drugs and endogenous compounds.
UGT enzymes have implications in inherited metabolic disorders like Crigler-Najjar syndrome which results from mutations in the gene encoding UGT1A1 leading to impaired bilirubin conjugation. UGT's activity is also linked to the development of hyperbilirubinemia or Gilbert's syndrome a milder condition characterized by intermittent jaundice. Additionally diseases such as cancer and the protein's interaction with other metabolic enzymes like GST (glutathione S-transferase) can modulate drug resistance affecting treatment outcomes.